Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment
with depot octreotide prolongs progression free survival compared to treatment with
octreotide alone in patients with advanced carcinoid tumor.